Telix Q2 Revenue Reaches $247M, FY2026 Guidance Lifted Above $1B
TLX sits 68% above its 52-week low of $6.28.
Summary
Telix posted Q2 2026 revenue of $247 million, a 21% year-over-year increase, and raised full-year guidance to over $1 billion. The update also highlighted progress across multiple late-stage pipeline programs, including FDA alignment on a pivotal prostate cancer trial and a September PDUFA date for its brain imaging agent.
Key Events · Earnings and Guidance · TLX
-
Q2 Revenue Beats, Guidance Raised
Revenue reached $247M in Q2 2026, a 21% year-over-year increase, with Precision Medicine up 30%. FY2026 revenue guidance was raised to over $1B, including $40M from Regeneron.
-
FDA Greenlights Pivotal Prostate Cancer Trial
The FDA confirmed that safety data from Part 1 of the ProstACT Global Phase 3 trial for TLX591-Tx are sufficient to proceed to Part 2 in the U.S., pending IND amendment review.
-
Brain Imaging NDA Accepted, PDUFA Set
The resubmitted NDA for Pixclara (TLX101-Px) was accepted by the FDA, with a PDUFA goal date of September 11, 2026. The European MAA was also validated.
-
Pipeline Advances Across Multiple Programs
The first patient was dosed in the LUTEON pivotal trial for kidney cancer; the IPAX BrIGHT pivotal trial for glioblastoma enrolled its first cohort; and the Japan Phase 3 study for Illuccix completed enrollment.
Analysis · TLX · Life Sciences
A 21% year-over-year revenue surge, fueled by the Precision Medicine segment, powered a standout quarter for Telix. The full-year outlook now exceeds $1 billion, incorporating a $40 million upfront payment from Regeneron alongside robust commercial momentum. Late-stage pipeline de-risking is evident across multiple fronts: FDA alignment on a pivotal prostate cancer trial, completed enrollment in a Japanese Phase 3 study, and acceptance of a brain imaging NDA with a September PDUFA date. Raising R&D spend to as much as $270 million underscores confidence in accelerating high-value programs, though it may weigh on near-term profitability. For a $3.5 billion biotech, crossing the $1 billion revenue threshold signals a transition to commercial scale, with the pipeline offering multiple shots on goal for further upside.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TLX was trading at $10.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.5B. The 52-week trading range was $6.28 to $16.94. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.